MIT Technology Review · 实时热榜

Outside the small town of Paducah, Kentucky, a wealth of uranium is locked away in thousands of storage cylinders filled with waste material from a now-closed nuclear enrichment facility. Lasers could help get it out. A company called Global Laser Enrichment (GLE) is looking to reprocess this old material with a new technology called laser…

This story originally appeared in The Algorithm, our weekly newsletter on AI. To get stories like this in your inbox first, sign up here. Reading OpenAI’s account last week of how some of its models broke their containment and hacked into the computer systems of Hugging Face, another AI company, was the first time I got…

Lee, an engineer at Samsung’s semiconductor division, clocks out when his shift ends. He used to work longer hours, going the extra mile to excel at his projects. But lately, he’s been coming straight home to work on his job application for the chipmaker’s South Korean rival SK Hynix, sharing tips with his coworkers on…

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. OpenAI called the Hugging Face attack unprecedented. But we’ve been here before. —Will Douglas Heaven, senior AI editor Reading OpenAI’s account last week of how some of its models broke their…

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. How lasers could help provide fuel for nuclear reactors Nuclear power provides about 9% of global electricity today, and that fraction could tick up as countries look to build new reactors.…

Imagine a healthcare system made up of multiple AI agents: one that manages symptom assessment, another scheduling, a third insurance, and a fourth pharmacy. Each is an expert in its domain. But they all have their own distinct knowledge and objectives. Today they can exchange data, but they are not yet able to actually coordinate…

Drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly defined by first-mover advantage. Since the 1950s, the cost of developing new pharmaceuticals has roughly doubled every nine years—a phenomenon known as Eroom’s Law. Today, bringing a new drug to market takes an average of 10-15 years and costs…

For the enterprise, the promise of agentic AI is much more than just a better chatbot. It is software agents that execute business tasks end-to-end across people, business workflows, data, and systems. The platform best-suited to run agents is built with proper CPU capacity, resilient data access, policy-aware tool use, observability, memory management, and the…

This week, I covered a fascinating effort to preserve organs outside the body. There’s a huge shortage of donor organs, and one of the main reasons is time—they survive only a matter of hours outside the body, even when they’re kept on ice. Doctors dream of organ banks—stores of human organs that can be preserved…

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Supercooled kidneys have been transplanted into pigs in a “landmark achievement” When it comes to organ donation, time is everything. As soon as an organ has been removed from a donor’s…

When it comes to organ donation, time is everything. As soon as an organ has been carefully removed from a donor’s body, it starts to deteriorate. Surgeons have a matter of hours to get it into a recipient. Leave it too long and the organ will become unusable. In most cases, organs will be kept…

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. The power line that could reshape New York’s grid is hitting snags During a heat wave on July 3, New York State’s grid imported enough electricity from Canada to meet about…

Designing and developing a new medicine is an expensive, failure-prone scientific challenge. A new drug can take many years to develop, at the cost of a significant investment. And even then, most possible candidates never reach the patient. For biologic medicines, therapies made from engineered proteins rather than synthetic chemistry (which are often used to…